RCUS Form 4 shows Arcus Biosciences president selling common stock

Q: What insider transaction did Arcus Biosciences (RCUS) report in this Form 4?

The Form 4 discloses that the President of Arcus Biosciences, Inc. (RCUS) reported sales of the company’s common stock on November 17 and 18, 2025 , executed through a trust.

Q: How many Arcus Biosciences (RCUS) shares were sold and at what prices?

The trust sold 37,114 shares at a weighted average price of $20.2274 , 7,836 shares at $20.713 , and 5,050 shares at $19.75 , with each block sold in multiple transactions within stated price ranges.

Q: What do the weighted average prices in the Arcus Biosciences Form 4 mean?

The prices reported ( $20.2274 , $20.713 , and $19.75 ) are weighted average prices for multiple trades executed in price ranges detailed in the footnotes, and the reporting person offers to provide full trade breakdowns upon request.

Q: What is the relationship of the reporting person to Arcus Biosciences (RCUS)?

The reporting person is identified as an officer of Arcus Biosciences, Inc., serving in the role of President , and files individually as one reporting person.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Arcus Biosciences, Inc. (RCUS) reported insider stock sales by its President, who is an officer of the company. On November 17, 2025, a trust associated with the reporting person sold 37,114 shares of common stock at a weighted average price of $20.2274, and a further 7,836 shares at a weighted average price of $20.713. On November 18, 2025, the trust sold an additional 5,050 shares at a weighted average price of $19.75. The filing states these transactions were executed under a Rule 10b5-1 trading plan adopted on August 8, 2025. After these sales, the reporting person beneficially owned 1,037,060 shares indirectly through a trust and 367,220 shares directly.

Insider Trade Summary

Net Seller: 50,000 shares ($1,012,764)

Net Sell 4 txns

Insider Jaen Juan C.

Role President

Sold 50,000 shs ($1.01M)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,050	$19.75	$100K
Sale	Common Stock	37,114	$20.2274	$751K
Sale	Common Stock	7,836	$20.713	$162K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,037,060 shares (Indirect, By Trust); Common Stock — 367,220 shares (Direct)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.65 to $20.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.65 to $20.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.48 to $20.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

11/19/2025 - 04:39 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaen Juan C.

(Last)

(First)

(Middle)

C/O ARCUS BIOSCIENCES, INC.

3928 POINT EDEN WAY

(Street)

HAYWARD

94545

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcus Biosciences, Inc. [ RCUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/17/2025		S		37,114⁽¹⁾	D	$20.2274⁽²⁾	1,049,946	I	By Trust
Common Stock	11/17/2025		S		7,836⁽¹⁾	D	$20.713⁽³⁾	1,042,110	I	By Trust
Common Stock	11/18/2025		S		5,050⁽¹⁾	D	$19.75⁽⁴⁾	1,037,060	I	By Trust
Common Stock								367,220	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.65 to $20.645, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.65 to $20.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

4. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.48 to $20.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Remarks:

	/s/ Carolyn Tang, Attorney-in-Fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Arcus Biosciences (RCUS) report in this Form 4?

The Form 4 discloses that the President of Arcus Biosciences, Inc. (RCUS) reported sales of the company’s common stock on November 17 and 18, 2025, executed through a trust.

How many Arcus Biosciences (RCUS) shares were sold and at what prices?

The trust sold 37,114 shares at a weighted average price of $20.2274, 7,836 shares at $20.713, and 5,050 shares at $19.75, with each block sold in multiple transactions within stated price ranges.

Was the Arcus Biosciences (RCUS) insider sale under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

How many Arcus Biosciences (RCUS) shares does the insider beneficially own after the sales?

Following the reported transactions, the reporting person beneficially owned 1,037,060 shares indirectly through a trust and 367,220 shares held directly.

What do the weighted average prices in the Arcus Biosciences Form 4 mean?

The prices reported ($20.2274, $20.713, and $19.75) are weighted average prices for multiple trades executed in price ranges detailed in the footnotes, and the reporting person offers to provide full trade breakdowns upon request.

What is the relationship of the reporting person to Arcus Biosciences (RCUS)?

The reporting person is identified as an officer of Arcus Biosciences, Inc., serving in the role of President, and files individually as one reporting person.